1. Scrip
  2. >>Therapy Areas

Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024

Phase III Data Also Show New Toxin Works Up To Six Months

 
• By Mandy Jackson

Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.

Wooden blocks with launching rocket graphic arranged in pyramid shape
Galderma is building up to its nemolizumab launch in the US next year • Source: Shutterstock

Galderma S.A.’s ongoing makeover continues with the skin care specialist revealing positive topline Phase III results in atopic dermatitis for nemolizumab. The first-in-class IL-31 receptor alpha inhibitor is poised to be the company’s first therapeutic biologic, advancing a long-term plan to shift its prescription dermatology medicines portfolio from topical treatments to systemic therapies.

Zug, Switzerland-based Galderma said on 13 March, as part of its fiscal year 2022 financial results, that it plans to launch nemolizumab in the US during the second half of 2024 in atopic dermatitis and prurigo nodularis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.